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maduro@Purpose: In young women, breast-conserving therapy (BCT), i.e., lumpectomy followed by radiotherapy, has been
associated with an increased risk of local recurrence. Still, there is insufficient evidence that BCT impairs survival.
The aim of our study was to compare the effect of BCTwith mastectomy on overall survival (OS) in young women
with early-stage breast cancer.
Methods and Materials: From two Dutch regional population-based cancer registries (covering 6.2 million
inhabitants) 1,453 women <40 years with pathologically T1N0–1M0 breast cancer were selected. Cox regression
survival analysis was used to study the effect of local treatment (BCT vs. mastectomy) stratified for nodal stage
on survival and corrected for tumor size, age, period of diagnosis, and use of adjuvant systemic therapy.
Results: With a median follow-up of 9.6 years, 10-year OS was 83% after BCTand 78% after mastectomy, respec-
tively (unadjusted hazard ratio [HR], 1.37; 95% confidence interval [CI], 1.09–1.72). In N0-patients, 10-year OS
was 84% after BCTand 81% after mastectomy and local treatment was not associated with differences in OS (HR
1.19; 95% CI, 0.89–1.58; p = 0.25). Within the N1-patient group, OS was better after BCT compared with mastec-
tomy, 79% vs. 71% at 10 years (HR 1.91; 95% CI, 1.28–2.84; p = 0.001) and in patients treated with adjuvant hor-
monal therapy (HR 0.34; 95% CI, 0.18–0.66; p = 0.001).
Conclusions: In this large population-based cohort of early-stage young breast cancer patients, 10-year OS was not
impaired after BCT compared with mastectomy. Patients with 1 to 3 positive lymph nodes had better prognosis
after BCT than after mastectomy.
 2011 Elsevier Inc. Open access under the Elsevier OA license.MastBreast cancer, Young age, Breast-conserving therapy,
INTRODUCTION
In the Netherlands, 5% of all women diagnosed with breast
cancer are younger than 40 years (1). Breast cancers in young
women generally have a higher proportion of pathologic fea-
tures associated with more aggressive tumor behavior, such
as negative estrogen receptor, poor differentiation grade
(Grade 3), and lymphovascular invasion (2, 3). However,
even if these differences are accounted for, young age
remains an independent risk factor associated with worse
clinical outcome, after both breast-conserving therapy
(BCT) and mastectomy (4–10). The risk of dying of breast
cancer within 5 years of diagnosis in women aged younger
than 35 with Stage I–IIb breast cancer has been reported told higher than in women aged 50 to 69 years (9).
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Like older women, young women with early stage breast
cancer are treated with either BCT or mastectomy. Young
women have worse local control rates after BCT, compared
with mastectomy (11–14). However, there is still controversy
as to whether this difference in local control translates into
inferior survival after BCT in young breast cancer patients
(11, 12, 15). In this study, we investigated the effect of type
of local treatment (BCT vs. mastectomy) on overall survival
(OS) of women aged <40 years with early-stage breast cancer.
METHODS AND MATERIALS
Study population
Patients were selected from two Dutch population-based cancerregistries (CR), including the Comprehensive Cancer Center North
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a population of approximately 6.2 million inhabitants (40% of
the Dutch population).
The Dutch CR record data of all newly diagnosed malignancies.
Notifications are obtained from the PathologyAutomated Archives.
Furthermore, additional data are received from the National Regis-
try of Hospital Discharge Diagnoses, which accounts for up to 8%
of new cases (16). Data are obtained from patient files and include
identifying information and tumor characteristics. Topography and
morphology are coded according to the International Classification
of Diseases for Oncology. TNM classification is used for staging
(International Union against Cancer 2002) (17). Moreover, data
on treatment (type of surgery, radiotherapy, chemotherapy, and hor-
monal therapy) are gathered on regular basis within the CR. The
quality of the Dutch cancer registries is high, and completeness is
estimated to be over 95% (18). Data on mortality are derived
from the Municipal Personal Records Database. In this study, last
linkage was set on February 1, 2009. For most patients under study,
the CR did not collect data on recurrent disease or distant metasta-
ses. Hormonal receptor status was not routinely assessed by the CR
in the beginning of the study period and was therefore not consid-
ered as covariate.
Female patients <40 years of age at diagnosis with invasive breast
cancer pathologically#2 cm (pT1a–c),with up to 3 lymphnodeme-
tastases (pN0-1) and treated with either BCT (breast-conserving
surgery and radiotherapy) ormastectomy,with orwithout radiother-
apy, between January 1989 and January 2005 were selected. We
only included patients with small tumors, suitable for lumpectomy
and up to 3 positive lymph nodes, because these patients are consid-
ered ideal for BCT (17). Choice of type of local treatment (BCT or
mastectomy) was based on the surgeons’ or patients’ preferences
(19, 20). Patients with distant metastatic (M1) disease, previous
diagnosis of invasive cancer except nonmelanoma skin cancer,
and patients treated with neoadjuvant therapy were excluded. The
cohort was composed in accordance to privacy regulations of the
Netherlands Cancer Registry.Table 1. Baseline characteristics of eligible patie
Characteristic
N0
BCT (n = 693) M (n = 357)
p value*
BCT (n =
n (%) n (%) n
Age at diagnosis (years)
<35 231 (33.3) 128 (35.9) 77 (
35–39 462 (66.7) 229 (64.1) 0.42 139 (
Period of diagnosis
1989–1994 259 (37.4) 139 (38.9) 76 (
1995–2000 213 (30.7) 104 (29.1) 60 (
2001–2004 221 (31.9) 114 (31.9) 0.84 80 (
Pathological T stage
1ab 173 (25.0) 106 (29.7) 39 (
1c 520 (75.0) 251 (70.3) 0.10 177 (
Adjuvant chemotherapy
No 544 (78.5) 280 (78.4) 34 (
Yes 149 (21.5) 77 (21.6) 0.98 182 (
Adjuvant hormonal
therapy
No 631 (91.1) 323 (90.5) 160 (7
Yes 62 (8.9) 37 (10.4) 0.76 56 (
Abbreviations: BCT = breast-conserving therapy; M = mastectomy.
* Estimated from chi-square analysis.
y Bold print indicates a p value <0.05.Patient characteristics
Ultimately, the study population comprised 1,453 patients.
Table 1 summarizes patient and tumor characteristics for both treat-
ment groups (BCT or mastectomy), both overall and stratified for
nodal stage. Median age was 36.5 (interquartile range, 33.8–38.4)
years. Median follow-up was 9.6 (interquartile range, 5.9–14.3)
years. Local treatment was BCT in 63% (n = 909) and mastectomy
in 37% (n = 544) of the patients. Within the mastectomy group, 125
(23%) women received adjuvant radiotherapy. The majority of
tumors (75%) were between 1 and 2 cm in diameter (pT1c), and
72% of patients had node-negative disease. Within the N0-group,
both local treatment groups were well balanced on all characteris-
tics. In the N1-group, the mastectomy group received more hor-
monal therapy than the BCT group (Table 1).Treatment
Patients were treated according to the national guidelines at time
of diagnosis. The guidelines for patients under 40 years of age are
outlined below.
Local treatment consisted of wide tumor excision or quadrantec-
tomy followed by radiotherapy to the whole breast with or without
a boost to the tumor bed area, or a mastectomy. In cases of positive
surgical margins or multifocality after mastectomy, surgery was
followed by chest wall irradiation. Axillary staging consisted of
axillary lymph node clearance, and, since the late 1990s, a sentinel
node biopsy was followed by axillary clearance in case of a positive
sentinel node.
Locoregional radiotherapy, consisting of irradiation of the drain-
ing nodal areas, such as axillary, supraclavicular, and internal mam-
mary chain, was indicated in cases of positive apical lymph nodes
and extensive extra nodal growth. From 1994 until 2003, internal
mammary chain irradiation was indicated in medial located tumors
in combination with 1 to 3 positive lymph nodes. After mastectomy,
locoregional radiotherapy always included irradiation to the chest
wall.nts according to local treatment (n = 1,453)
N1 All N
216) M (n = 187)
p value*
BCT (n = 909) M (n = 544)
p value*(%) n (%) n (%) n (%)
35.6) 71 (38.0) 308 (33.9) 199 (36.6)
64.4) 116 (62.0) 0.63 601 (66.1) 345 (63.4) 0.30
35.2) 53 (28.3) 335 (36.9) 192 (35.3)
27.8) 61 (32.6) 273 (30.0) 165 (30.3)
37.0) 73 (39.0) 0.31 301 (33.1) 187 (34.4) 0.82
18.1) 45 (24.1) 212 (23.3) 151 (27.8)
81.9) 142 (75.9) 0.14 697 (76.7) 393 (72.2) 0.06
15.7) 22 (11.8) 578 (63.6) 302 (55.5)
84.3) 165 (88.2) 0.25 331 (36.4) 242 (44.5) 0.002y
4.1) 121 (64.7) 791 (87.0) 444 (81.6)
25.9) 66 (35.3) 0.041 118 (13.0) 100 (18.4) 0.005
Fig. 1. Overall survival of patients after breast conserving therapy
(BCT) or mastectomy (M) (unadjusted hazard ratio 1.37; 95% con-
fidence interval, 1.09–1.72; p = 0.007).
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ation were based on tumor characteristics acquired after primary
surgery and had no influence on the surgeons’ choice for either
breast-conserving surgery or mastectomy.
In the 1980s and early 1990s, only node-positive patients were
treated with adjuvant chemotherapy, generally consisting of cyclo-
phosphamide, methotrexate, and 5-fluorouracil. Anthracycline-
based chemotherapy was increasingly used from the mid-1990s.
In the late 1990s, chemotherapy was also indicated for premeno-
pausal, high-risk, node-negative patients, depending on tumor
size, grade, and hormonal receptor status. Around 2001, adjuvant
systemic treatment indications were expanded to patients aged
#35 years, irrespective of their lymph node status or primary tumor
characteristics.
Hormonal status was assessed routinely after 1998, and since
then adjuvant hormonal therapy was added to chemotherapy in
all hormone receptor-positive, node-positive patients and unfavor-
able node-negative patients (21, 22). In the Netherlands,
trastuzumab as adjuvant treatment for breast cancer patients was
introduced in 2005 and therefore not part of standard treatment in
this cohort.Statistical analysis
Patient characteristics were described by local treatment and com-
pared with the chi-square test. The unadjusted 5- and 10-year actuar-
ial rates of OS were calculated using the Kaplan-Meier method, and
both treatment groups were compared with the log-rank test.
Because significant interaction was present between local treat-
ment and nodal stage, we analyzed the data for node-negative and
node-positive patients separately.
Multivariate analysis was performed using the Cox proportional
hazard model to study the effect of local treatment (BCTor mastec-
tomy) on OS. In the analysis, we corrected for pathological tumor
size (pT1ab/T1c), age at diagnosis (< 35/35-39), adjuvant chemo-
therapy (no/yes), adjuvant hormonal therapy (no/yes), and period
of diagnosis (1989–1994/1995–2000/2001–2004). In general, these
time periods corresponded with changes in systemic therapy guide-
lines. The OS was calculated as the interval between pathological
diagnosis and date of death.
Because of the relatively young age of the cohort, we report OS
and not only breast cancer–related deaths. In this way, we take
potential treatment related long-term toxicity deaths into account.
Model fit was evaluated using residual-based graphical methods
and goodness-of-fit statistics. All tests were two-sided, and a p
value <0.05 was considered statistically significant. Interaction
with local treatment was tested and for the interaction terms signif-
icance was set on 0.1. Analyses were performed using the STATA
software package, version 10.1 for Windows (Stata Corporation
LP, College Station, TX).RESULTS
Overall survival
The 10-year actuarial OS rate was 83% in the BCT group
vs. 78% in the mastectomy group (log-rank test p = 0.007;
unadjusted hazard ratio [HR] 1.37; 95% confidence interval
[CI], 1.09–1.72; Figure 1). In total, 302 (21%) patients died
during follow-up (Table 2). Patients without lymph node
metastasis had a significantly better 10-year survival than
node-positive patients (log-rank test p < 0.001; unadjusted
HR 1.55; 95% CI, 1.22–1.96), 83% and 75%, respectively.Because a significant interaction was present between
local treatment and nodal stage (p = 0.099), we analyzed
the data for node-negative and node-positive patients sepa-
rately (Fig. 2A and 2B). Events and actuarial OS rates for
both subgroups are presented in Table 2. In patients without
lymph node metastases, no significant difference was seen in
OS between treatment groups (log-rank test p = 0.26; unad-
justed HR 1.18; 95% CI, 0.88–1.57). In node-positive dis-
ease, patients with mastectomy had a significantly worse
OS outcome (log-rank test p = 0.014; unadjusted HR 1.62;
95% CI, 1.10–2.40) compared with patients who had BCT.
The stratified multivariate analysis of OS in node-negative
patients is shown in Table 3. Local treatment was not asso-
ciated with OS in this subgroup (HR 1.19; 95% CI, 0.89–
1.58; p = 0.247). Women diagnosed and treated in the period
2000–2004 had significantly better survival than patients
diagnosed before 1994 (HR 0.56; 95% CI, 0.33–0.96; p =
0.034; overall p = 0.053).
The effect of local treatment in patients with positive
lymph nodes is shown in Table 4. In node-positive patients,
mastectomy was independently associated with worse OS
(HR 1.91; 95% CI, 1.28–2.84; p = 0.001). Furthermore,
patients treated with adjuvant hormonal therapy had better
OS than patients without hormonal therapy (HR 0.34; 95%
CI, 0.18–0.66; p = 0.001).
In total, 6.9% of patients developed contralateral breast
cancer as first event and 4.1% of the patients developed
a non-breast-cancer malignancy. Excluding these second
cancer cases from the analysis did not alter the OS results
(data not shown).
DISCUSSION
In this population-based analysis among young women
with early-stage breast cancer, OS was not impaired after
BCT compared with mastectomy. In node-positive patients,
OS was better, even after correction for other prognostic
Table 2. Patient follow-up and events stratified for nodal stage (n = 1,453)
Characteristic
N0 N1 all N
BCT M BCT M BCT M
Patients, n (%) 693 (66.0%) 357 (34.0%) 216 (53.6%) 187 (46.4%) 909 (62.6%) 544 (37.4%)
Age at diagnosis (years)
Median 36.5 36.4 36.9 36.5 36.6 36.4
ICR 33.9–38.5 33.8–38.2 33.4–38.7 33.8–38.3 33.9–38.5 33.8–38.2
Follow-up (years)
Median 10.0 9.8 9.6 7.0 9.9 8.9
ICR 6.4–14.8 6.3–14.6 5.5–14.8 4.6–11.4 6.1–14.8 5.7–13.6
10-year OS
At risk at 10 years 346 176 105 67 451 243
OS 84% 81% 79% 71% 83% 78%
Abbreviations: BCT = breast-conserving therapy; M = mastectomy; ICR = interquartile range; OS = overall survival.
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comparing mastectomy to BCT in young breast cancer
patients (aged <40 years) who are ideal candidates
(pT1N0–1M0) for BCT.0.2
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Fig. 2. Overall survival of patients after breast conserving therapy
(BCT) or mastectomy (M) in node-negative patients (A); (unad-
justed hazard ratio 1.18; 95% confidence interval, 0.88–1.57; p =
0.26) and node-positive patients (B); (unadjusted hazard ratio
1.62; 95% confidence interval, 1.10–2.40; p = 0.014).The overall actuarial 10-year OS rate was 83% in the BCT
group vs. 78% in the mastectomy group. These OS rates and
the difference between BCT and mastectomy are compara-
ble to other long-term outcomes from retrospective series.
In women 35 years and younger with Stage I–III disease,
Beadle et al. (23) described 10-year OS rates of 80% and
59% for BCT and mastectomy, respectively. In a favorable
subset-analysis among Stage I young breast cancer patients,
<40 years, considered ideal candidates for BCT, breast-
cancer-specific survival (BCSS) at 10 years was 91% in
the BCT group vs. 86% after mastectomy (15).
Node-negative patients diagnosed after 2000 had better
OS than patients treated before 1994 (HR 0.56; 95% CI,
0.33–0.96; p = 0.034, overall p = 0.053). By including period
of diagnosis in our analysis, we tried to adjust for changes in
systemic treatment over time. Because of guideline changes,
more patients received a combination of both adjuvantTable 3. Multivariate Cox regression survival analysis
stratified for nodal stage
Node-negative patients (n = 1,050)
Characteristic n HR (95% CI) p value
Age at diagnosis (y)
<35 359 1
35–39 691 0.84 (0.63–1.12) 0.24
Period of diagnosis
1989–1994 398 1 0.053
1995–2000 317 1.07 (0.78–1.47) 0.66
2001–2004 335 0.56 (0.33–0.96) 0.034*
Local treatment
BCT 693 1
M 357 1.19 (0.89–1.58) 0.25
Pathological T stage
1ab 279 1
1c 771 1.01 (0.73–1.38) 0.97
Adjuvant chemotherapy
No 824 1
Yes 226 0.89 (0.53–1.50) 0.66
Adjuvant hormonal therapy
No 954 1
Yes 96 0.46 (0.16–1.33) 0.15
Abbreviations: BCT = breast-conserving therapy; CI = confi-
dence interval; HR = hazard ratio; M = mastectomy.
* Bold print indicates a p value <0.05.
Table 4. Multivariate Cox regression survival analysis
stratified for nodal stage
Node-positive patients (n = 403)
Characteristic n HR (95% CI) p value
Age at diagnosis (years)
<35 148 1
35–39 255 0.68 (0.46–1.01) 0.056
Period of diagnosis
1989–1994 129 1 0.37
1995–2000 121 0.73 (0.45–1.18) 0.20
2001–2004 153 1.03 (0.58–1.83) 0.93
Local treatment
BCT 216 1
M 187 1.91 (1.28–2.84) 0.001*
Pathological T stage
1ab 84 1
1c 319 1.25 (0.75–2.09) 0.39
Adjuvant chemotherapy
No 56 1
Yes 347 0.70 (0.42–1.17) 0.18
Adjuvant hormonal therapy
No 281 1
Yes 122 0.34 (0.18–0.66) 0.001
Abbreviations: BCT = breast-conserving therapy; CI = confi-
dence interval; HR = hazard ratio; M = mastectomy.
* Bold print indicates a p value <0.05.
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2000. An improvement in outcome in node-negative patients
by period of diagnosis was also observed in the study by van
der Sangen et al. (24). There were no differences in the
choice of local treatment in the different periods (data not
shown). In our study, no relation was found between local
treatment and OS among patients with node-negative
disease.
In the node-positive (1 to 3 positive lymph nodes) patients,
OS rate was better in patients after BCT compared with mas-
tectomy, similar to the results of Beadle et al. (23), who found
mastectomy to be predictive of inferior OS (81% vs. 63% at
10 years) in 296 Stage II patients. The analysis of Surveil-
lance, Epidemiology, and End Results data showed that ra-
diotherapy was independently associated with improved
OS in patients with Stage II breast cancer with 1–3 positive
lymph nodes. At 10 years, BCSS was 88% for pT1 patients
after BCT compared with 84% after mastectomy without ra-
diotherapy (p < 0.001) (25). In this study, we have found
a similar advantage favoring BCT in a population of young
women with Stage IIa (excluding T2N0) breast cancer.
Radiotherapy has shown to improve OS after mastectomy
and adjuvant systemic therapy (26), yet there is still debate
as to whether this applies to all node-positive patients (27).
In a subgroup analysis of the Danish Breast Cancer Cooper-
ative Group b and c trials in patients with 1 to 3 positive
lymph nodes, postmastectomy radiotherapy improved the
absolute 15-year OS with 9% (relative risk reduction of
17%) (28). In the British Columbia trial, the 20-year BCSS
improved by 15% in irradiated patients, the relative risk
reduction was 23% and 24% in patients with 1 to 3 and
$4 positive lymph nodes, respectively (29). MacDonaldet al. (30) showed in a recent retrospective analysis an
18% absolute 10-year OS gain after chest wall irradiation
compared with no irradiation in Stage II patients after mas-
tectomy (30). These studies show a beneficial role of post-
mastectomy radiotherapy in Stage II patients. The
difference we found in survival between the mastectomy
and the BCT group might reflect the beneficial effect of
radiotherapy, which was given to all BCT patients. Involve-
ment of 1 to 3 lymph nodes was not an indication for post-
mastectomy radiotherapy in this study.
In our population, all patients received radiotherapy after
breast-conserving surgery, which was not the case after mas-
tectomy. Although it was possible to identify the patients
receiving postmastectomy radiotherapy, it was not possible
to distinguish in the breast-conserved group which patients
received additional regional radiotherapy. Patients receiving
regional radiotherapy would represent an unfavorable group,
which cannot be accounted for in the BCT group. To prevent
a selection bias and in the knowledge that the indication for
locoregional irradiation was based on postsurgery findings,
we did not include postmastectomy irradiation in our com-
parison between BCT and mastectomy. The OS of patients
receiving postmastectomy radiotherapy, which was a prog-
nostically unfavorable group, was equivalent to that of the
patients undergoing mastectomy without radiotherapy
(data not shown). Beadle et al. (23) showed that in patients
with Stage II disease, after BCT and postmastectomy radio-
therapy, the OS was the same, despite higher locoregional
recurrence rates after BCT. Furthermore, the difference in
locoregional recurrence rates after mastectomy with or with-
out adjuvant radiotherapy translated in a survival advantage
favoring the postmastectomy radiotherapy. This shows that
the impact of locoregional recurrences on survival is differ-
ent after BCT compared with mastectomy.
In this study, we evaluated survival regardless of local
recurrence. Moreover, the number of local recurrences after
BCT is expected to be higher than after mastectomy (7, 11–
14, 24, 31). Even with the higher expected local recurrence
rate, BCT resulted in a survival advantage over mastectomy
in patients with 1 to 3 positive nodes. This suggests that OS
differences in this lymph node–positive population are truly
affected by choice of treatment.
Adjuvant hormonal therapy did significantly affect OS in
node-positive patients. Similar results have been reported in
a large meta-analysis of the Early Breast Cancer Trialists’
Collaborative Group (EBCTCG) (32), in which adjuvant
hormonal therapy yielded significantly better survival in
women 50 years and younger.
Limitations of this study are the retrospective design,
which bears a risk of selection bias and the lack of informa-
tion on other known prognostic factors, such as differentia-
tion grade and receptor status. However, it is unlikely that
these tumor-related prognostic factors have contributed to
the choice of surgical procedure because at the time the
women in this study were treated, these factors were
assessed postoperatively and not taken into account for the
type of surgery. Furthermore, to limit an eventual selection
e558 I. J. Radiation Oncology d Biology d Physics Volume 81, Number 4, 2011bias by the surgeon, only tumors with a maximum diameter
of 2 cm were included. For most tumors 2 cm and smaller,
breast size would not be a factor accounting for the type of
surgery. Choice of surgery in this population was based on
surgeons’ or patients’ preferences, with large variations
between regions and hospitals (19, 20). Multifocality,
which is a risk factor for local recurrence (33–35), cannot
be excluded as cause of selection bias but would, at the
most, result in impaired results for the BCT group. In
addition, because the CR did not gather data on prognostic
factors and disease-related events, the impact of these events
on OS could not be investigated. The node-positive mastec-tomy patients received significantly more adjuvant hormonal
therapy compared with the BCT group, which at the least
would benefit the mastectomy group.
In conclusion, in this large cohort of young, early-stage
breast cancer patients, 10-year OS was not impaired after
BCT compared with mastectomy. In patients with 1 to 3 pos-
itive lymph nodes, OS was better after BCT compared with
mastectomy. Consequently, the study results do not justify
withholding BCT from women younger than 40 years with
early-stage breast cancer and adds on the mounting evidence
in favor of radiotherapy for patients with 1 to 3 lymph nodes
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